Docket No. CELL-0102

ABSTRACT

Pyrimidines of formula (1) are described



(1)

wherein Ar is an optionally substituted aromatic or heteroaromatic group;
R^1 is a hydrogen atom or a straight or branched chain alkyl group;
R^2 is a $-X^1-R^3$ group where X^1 is a direct bond or a linker atom or group, and
R^3 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group;
and the salts, solvates, hydrates and N-oxides thereof.

The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.